Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CODX.O
stocks logo

CODX.O

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
300.00K
+100.9%
-0.160
-55.56%
300.00K
+496.66%
-0.120
-50%
300.00K
+84.15%
-0.100
-56.52%
Estimates Revision
The market is revising No Change the revenue expectations for Co-Diagnostics, Inc. (CODX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -1.12%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+2.74%
In Past 3 Month
Stock Price
Go Down
down Image
-1.12%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Co-Diagnostics Inc (CODX.O) is -0.70, compared to its 5-year average forward P/E of 6.27. For a more detailed relative valuation and DCF analysis to assess Co-Diagnostics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
6.27
Current PE
-0.70
Overvalued PE
23.97
Undervalued PE
-11.43

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
5.65
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
23.81
Undervalued EV/EBITDA
-12.51

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
11.80
Current PS
0.33
Overvalued PS
23.50
Undervalued PS
0.10
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CODX.O News & Events

Events Timeline

(ET)
2025-11-05
09:04:49
Co-Diagnostics appoints Maxim Group as financial advisor for CoSara Diagnostics
select
2025-11-04 (ET)
2025-11-04
08:45:02
Significant Borrowing Rate Hikes Among Liquid Assets
select
2025-11-03 (ET)
2025-11-03
09:04:24
Co-Diagnostics establishes a new division focused on AI
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-14PRnewswire
Co-Diagnostics Reports Third Quarter 2025 Financial Results

  • Financial Performance: Co-Diagnostics reported a revenue of $0.1 million for Q3 2025, down from $0.6 million in Q3 2024, with a net loss of $5.9 million, an improvement from a $9.7 million loss in the previous year.

  • Strategic Initiatives: The company closed a Registered Direct Offering (RDO) raising approximately $3.8 million and announced a joint venture with Arabian Eagle Manufacturing to expand its presence in the MENA region.

  • Technological Developments: Co-Diagnostics launched a new AI business unit to enhance its Co-Dx Primer Ai platform and developed a proprietary sample preparation instrument for its PCR Mycobacterium Tuberculosis Test.

  • Future Outlook: CEO Dwight Egan emphasized the importance of upcoming strategic initiatives, including potential SPAC transactions for its India joint venture, CoSara Diagnostics, and the localization of advanced molecular diagnostics in rapidly growing healthcare markets.

[object Object]
Preview
9.5
11-13NASDAQ.COM
Ardent Health, Inc. (ARDT) Exceeds Expectations for Q3 Earnings and Revenue

  • Earnings Performance: Ardent Health, Inc. reported quarterly earnings of $0.52 per share, exceeding the Zacks Consensus Estimate of $0.42, and showing significant growth from $0.19 per share a year ago. The company has consistently surpassed earnings estimates over the last four quarters.

  • Revenue Growth: The company generated revenues of $1.58 billion for the quarter, surpassing expectations by 1.55% and increasing from $1.45 billion year-over-year.

  • Stock Outlook: Despite the positive earnings report, Ardent Health's shares have declined by 17.7% since the start of the year, underperforming the S&P 500's 16.4% gain. The stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.

  • Industry Context: The Medical Services industry, to which Ardent Health belongs, is currently ranked in the bottom 41% of Zacks industries, suggesting that broader industry trends may impact the stock's future performance.

[object Object]
Preview
7.5
11-12PRnewswire
Utah Governor Cox and BioUtah Recognize Co-Diagnostics Following Recent JV Announcement in Kingdom of Saudi Arabia

  • Recognition of Co-Diagnostics: Governor Spencer Cox and Kelvyn Cullimore of BioUtah commend Co-Diagnostics, Inc. for its recent formation of CoMira Diagnostics, a joint venture in Saudi Arabia, highlighting the company's global competitiveness and contributions to the life sciences sector in Utah.

  • Expansion into International Markets: The joint venture in Saudi Arabia signifies Co-Diagnostics' growing leadership and presence in the international diagnostics market, showcasing the strength of Utah's entrepreneurial spirit.

  • About Co-Diagnostics: Co-Diagnostics, Inc. specializes in developing advanced molecular diagnostic tests, utilizing proprietary technology for detecting nucleic acid molecules and creating specific tests for various applications.

  • Community Impact: The achievements of Co-Diagnostics are seen as a representation of the rapidly growing life sciences community in Utah, with local leaders expressing pride in the company's contributions to global health.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Co-Diagnostics Inc (CODX.O) stock price today?

The current price of CODX.O is 0.3164 USD — it has decreased -4.53 % in the last trading day.

arrow icon

What is Co-Diagnostics Inc (CODX.O)'s business?

Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.

arrow icon

What is the price predicton of CODX.O Stock?

Wall Street analysts forecast CODX.O stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CODX.O is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Co-Diagnostics Inc (CODX.O)'s revenue for the last quarter?

Co-Diagnostics Inc revenue for the last quarter amounts to 145.38K USD, decreased -77.32 % YoY.

arrow icon

What is Co-Diagnostics Inc (CODX.O)'s earnings per share (EPS) for the last quarter?

Co-Diagnostics Inc. EPS for the last quarter amounts to -0.16 USD, decreased -50.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Co-Diagnostics Inc (CODX.O)'s fundamentals?

The market is revising No Change the revenue expectations for Co-Diagnostics, Inc. (CODX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -1.12%.
arrow icon

How many employees does Co-Diagnostics Inc (CODX.O). have?

Co-Diagnostics Inc (CODX.O) has 132 emplpoyees as of November 18 2025.

arrow icon

What is Co-Diagnostics Inc (CODX.O) market cap?

Today CODX.O has the market capitalization of 19.47M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto Tracker
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free